Trial Information

Summary: SWOG 9346: Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer, Phase III

The purpose of this research study is to evaluate the use of a drug called Zoladex in combination with an anti-androgen drug called Casodex in patients with advanced prostate cancer. Additional purposes are to determine the side effects of this treatment, how often they occur, and the quality of life for subjects on this treatment.

Patient Inclusion/Exclusion Criteria:

- At least 18 years of age - Diagnosed with Stage D2 prostate cancer - No prior bilateral orchiectomy (surgical removal of both testicles)
- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: October 6, 2008 at 2:28:23 PM